Abstract:Tau phosphorylation at specific Alzheimer's disease (AD)‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. ATP levels were reduced in cells expressing either tau pseudophosphorylated at S396/404 (2EC) or T231/S235 (2EM), and ROS production increased in 2EC cells during oxidation of succinate compared to wild type (T4)‐expressing cells. Thapsigargin reduced mitochondrial membrane potential (Ψm) and increased ROS production in both 2EC and 2EM cells. Altogether, these findings extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD. The thickness of the green arrows corresponds with the magnitude of effect. The longer red and black arrows represent experiments conducted with stressors and in the basal state, respectively. Phosphorylation of tau at sites associated with Alzheimer's disease (AD) likely plays a role in the disease progression. Mitochondrial impairment, correlating with increased presence of phosphorylated tau, has been identified as a contributing factor to neurodegenerative processes in AD. However, how tau phosphorylated at specific sites impacts mitochondrial function has not been fully defined. We examined how AD‐relevant phosphomimetics of tau impact selected aspects of mitochondrial biology. To mimic phosphorylation at AD‐associated sites, the serine/threonine (Ser/Thr) sites in wild‐type green fluorescent protein (GFP)‐tagged tau (T4) were converted to glutamic acid (E) to make pseudo‐phosphorylated GFP‐tagged Ser‐396/404 (2EC) and GFP‐tagged Thr‐231/Ser‐235 (2EM) constructs. These constructs were expressed in immortalized mouse hippocampal neuronal cell lines, and their impact on specific mitochondrial functions and responses to stressors were measured. Phosphomimetic tau altered mitochondrial distribution. Specifically, mitochondria accumulated in the soma of cells expressing either 2EC or 2EM and neurite‐like extensions in 2EC cells were shorter. Additionally, adenosine triphosphate levels were reduced in both 2EC‐ and 2EM‐expressing cells, and reactive oxygen species (ROS) production increased in 2EC cells during oxidation of succinate when compared to T4‐expressing cells. Thapsigargin reduced mitochondrial membrane potential and increased ROS production in both 2EC and 2EM cells relative to T4 cells, with no significant difference in the effects of rotenone. These results show that tau phosphorylation at specific AD‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. Altogether, these findings show that phosphorylated tau increases mitochondrial susceptibility to stressors and extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD.

Defined Tau Phosphospecies Differentially Inhibit Fast Axonal Transport Through Activation of Two Independent Signaling Pathways

Pseudo-phosphorylation at AT8 Epitopes Regulates the Tau Truncation at Aspartate 421

Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation.

Tau phosphosignatures discriminate Alzheimer Disease from other tauopathies

Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease

Site‐specific phosphorylation of tau impacts mitochondrial function and response to stressors

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

O4‐12‐03: Brain Phosphoproteome Network Analysis Discriminates Alzheimer's Disease from Other Tauopathies

Alzheimer’s disease: Ablating single master site abolishes tau hyperphosphorylation

A Unique Tau Conformation Generated by an Acetylation-Mimic Substitution Modulates P301S-dependent Tau Pathology and Hyperphosphorylation.

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Phosphorylation of Tau R2 Repeat Destabilizes Its Binding to Microtubules: A Molecular Dynamics Simulation Study

Single-molecule imaging of Tau reveals how phosphorylation affects its movement and confinement in living cells

Mass spectrometry identifies tau C-terminal phosphorylation cluster during neuronal hyperexcitation

Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein

Tau phosphorylation suppresses oxidative stress-induced mitophagy via FKBP8 receptor modulation

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

Developmental Regulation of Tau Phosphorylation, Tau Kinases, and Tau Phosphatases

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice